Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Development of a highly efficient decontamination approach for ceftolozane in the pharmaceutical manufacturing environment.

Yang RS, Zhang LK, Helmy R, Andreani T, Liu Z, Sheng H.

J Pharm Biomed Anal. 2020 Jan 5;177:112846. doi: 10.1016/j.jpba.2019.112846. Epub 2019 Aug 29.

PMID:
31522097
2.

Comparison of antiproliferative effect of epigallocatechin gallate when loaded into cationic solid lipid nanoparticles against different cell lines.

Silva AM, Martins-Gomes C, Fangueiro JF, Andreani T, Souto EB.

Pharm Dev Technol. 2019 Dec;24(10):1243-1249. doi: 10.1080/10837450.2019.1658774. Epub 2019 Sep 11.

PMID:
31437118
3.

The Influence of Polysaccharide Coating on the Physicochemical Parameters and Cytotoxicity of Silica Nanoparticles for Hydrophilic Biomolecules Delivery.

Andreani T, Fangueiro JF, Severino P, Souza ALR, Martins-Gomes C, Fernandes PMV, Calpena AC, Gremião MP, Souto EB, Silva AM.

Nanomaterials (Basel). 2019 Jul 27;9(8). pii: E1081. doi: 10.3390/nano9081081.

4.

GADD45 promotes locus-specific DNA demethylation and 2C cycling in embryonic stem cells.

Schüle KM, Leichsenring M, Andreani T, Vastolo V, Mallick M, Musheev MU, Karaulanov E, Niehrs C.

Genes Dev. 2019 Jul 1;33(13-14):782-798. doi: 10.1101/gad.325696.119. Epub 2019 Jun 6.

PMID:
31171699
5.

The aggressive call of Dendropsophus cruzi (Pombal Bastos, 1998) (Anura; Hylidae) in Central Brazil.

Andreani TL, Oliveira SR, Guerra V, Bastos RP, De Morais AR.

Zootaxa. 2018 Feb 13;4379(1):137-139. doi: 10.11646/zootaxa.4379.1.9.

PMID:
29689979
6.

Asymmetric Hydrogen Bonding Catalysis for the Synthesis of Dihydroquinazoline-Containing Antiviral, Letermovir.

Chung CK, Liu Z, Lexa KW, Andreani T, Xu Y, Ji Y, DiRocco DA, Humphrey GR, Ruck RT.

J Am Chem Soc. 2017 Aug 9;139(31):10637-10640. doi: 10.1021/jacs.7b05806. Epub 2017 Jul 25.

PMID:
28737937
7.

Influence of the stabilizers on the toxicity of metallic nanomaterials in aquatic organisms and human cell lines.

Andreani T, Nogueira V, Pinto VV, Ferreira MJ, Rasteiro MG, Silva AM, Pereira R, Pereira CM.

Sci Total Environ. 2017 Dec 31;607-608:1264-1277. doi: 10.1016/j.scitotenv.2017.07.098. Epub 2017 Jul 18.

PMID:
28732404
8.

d-α-tocopherol nanoemulsions: Size properties, rheological behavior, surface tension, osmolarity and cytotoxicity.

Teixeira MC, Severino P, Andreani T, Boonme P, Santini A, Silva AM, Souto EB.

Saudi Pharm J. 2017 Feb;25(2):231-235. doi: 10.1016/j.jsps.2016.06.004. Epub 2016 Jun 22.

9.

Microemulsion and Microemulsion-Based Gels for Topical Antifungal Therapy with Phytochemicals.

Boonme P, Kaewbanjong J, Amnuaikit T, Andreani T, Silva AM, Souto EB.

Curr Pharm Des. 2016;22(27):4257-63. Review.

PMID:
27262324
10.

Toxicological impact of cadmium-based quantum dots towards aquatic biota: Effect of natural sunlight exposure.

Silva BF, Andreani T, Gavina A, Vieira MN, Pereira CM, Rocha-Santos T, Pereira R.

Aquat Toxicol. 2016 Jul;176:197-207. doi: 10.1016/j.aquatox.2016.05.001. Epub 2016 May 3.

PMID:
27162069
11.

Potential Co-Factor Role of Tobacco Specific Nitrosamine Exposures in the Pathogenesis of Fetal Alcohol Spectrum Disorder.

Zabala V, Silbermann E, Re E, Andreani T, Tong M, Ramirez T, Gundogan F, de la Monte SM.

Gynecol Obstet Res. 2016 Apr;2(5):112-125. doi: 10.17140/GOROJ-2-125. Epub 2016 Mar 15.

12.

Biopharmaceutical evaluation of epigallocatechin gallate-loaded cationic lipid nanoparticles (EGCG-LNs): In vivo, in vitro and ex vivo studies.

Fangueiro JF, Calpena AC, Clares B, Andreani T, Egea MA, Veiga FJ, Garcia ML, Silva AM, Souto EB.

Int J Pharm. 2016 Apr 11;502(1-2):161-9. doi: 10.1016/j.ijpharm.2016.02.039. Epub 2016 Feb 24.

PMID:
26921515
13.

Differential Effects of 3rd Trimester-Equivalent Binge Ethanol and Tobacco-Specific Nitrosamine Ketone Exposures on Brain Insulin Signaling in Adolescence.

Andreani T, Tong M, Gundogan F, Silbermann E, de la Monte SM.

J Diabetes Relat Disord. 2016;1(1). pii: 105. Epub 2016 Feb 26.

14.

Potential Contributions of the Tobacco Nicotine-Derived Nitrosamine Ketone to White Matter Molecular Pathology in Fetal Alcohol Spectrum Disorder.

Tong M, Andreani T, Krotow A, Gundogan F, de la Monte SM.

Int J Neurol Brain Disord. 2016;3(2). doi: 10.15436/2377-1348.16.729. Epub 2016 Jul 20.

15.

Genetics of Circadian Rhythms.

Andreani TS, Itoh TQ, Yildirim E, Hwangbo DS, Allada R.

Sleep Med Clin. 2015 Dec;10(4):413-21. doi: 10.1016/j.jsmc.2015.08.007. Review.

16.

Hydrophilic Polymers for Modified-Release Nanoparticles: A Review of Mathematical Modelling for Pharmacokinetic Analysis.

Andreani T, Fangueiro JF, Jose S, Santini A, Silva AM, Souto EB.

Curr Pharm Des. 2015;21(22):3090-6. Review.

PMID:
26027576
17.

Effect of mucoadhesive polymers on the in vitro performance of insulin-loaded silica nanoparticles: Interactions with mucin and biomembrane models.

Andreani T, Miziara L, Lorenzón EN, de Souza AL, Kiill CP, Fangueiro JF, Garcia ML, Gremião PD, Silva AM, Souto EB.

Eur J Pharm Biopharm. 2015 Jun;93:118-26. doi: 10.1016/j.ejpb.2015.03.027. Epub 2015 Apr 3.

PMID:
25843239
18.

Tramadol hydrochloride: pharmacokinetics, pharmacodynamics, adverse side effects, co-administration of drugs and new drug delivery systems.

Vazzana M, Andreani T, Fangueiro J, Faggio C, Silva C, Santini A, Garcia ML, Silva AM, Souto EB.

Biomed Pharmacother. 2015 Mar;70:234-8. doi: 10.1016/j.biopha.2015.01.022. Epub 2015 Feb 7. Review.

PMID:
25776506
19.

Essential oils as active ingredients of lipid nanocarriers for chemotherapeutic use.

Severino P, Andreani T, Chaud MV, Benites CI, Pinho SC, Souto EB.

Curr Pharm Biotechnol. 2015;16(4):365-70. Review.

PMID:
25658380
20.

Silica-based matrices: State of the art and new perspectives for therapeutic drug delivery.

Andreani T, Silva AM, Souto EB.

Biotechnol Appl Biochem. 2015 Nov-Dec;62(6):754-64. doi: 10.1002/bab.1322. Epub 2015 May 19. Review.

PMID:
25471460
21.

Surface engineering of silica nanoparticles for oral insulin delivery: characterization and cell toxicity studies.

Andreani T, Kiill CP, de Souza AL, Fangueiro JF, Fernandes L, Doktorovová S, Santos DL, Garcia ML, Gremião MP, Souto EB, Silva AM.

Colloids Surf B Biointerfaces. 2014 Nov 1;123:916-23. doi: 10.1016/j.colsurfb.2014.10.047. Epub 2014 Oct 30.

PMID:
25466464
22.

Physicochemical characterization of epigallocatechin gallate lipid nanoparticles (EGCG-LNs) for ocular instillation.

Fangueiro JF, Andreani T, Fernandes L, Garcia ML, Egea MA, Silva AM, Souto EB.

Colloids Surf B Biointerfaces. 2014 Nov 1;123:452-60. doi: 10.1016/j.colsurfb.2014.09.042. Epub 2014 Sep 28.

PMID:
25303852
23.

Preparation and characterization of PEG-coated silica nanoparticles for oral insulin delivery.

Andreani T, de Souza AL, Kiill CP, Lorenzón EN, Fangueiro JF, Calpena AC, Chaud MV, Garcia ML, Gremião MP, Silva AM, Souto EB.

Int J Pharm. 2014 Oct 1;473(1-2):627-35. doi: 10.1016/j.ijpharm.2014.07.049. Epub 2014 Jul 30.

PMID:
25089510
24.

Cationic solid lipid nanoparticles interfere with the activity of antioxidant enzymes in hepatocellular carcinoma cells.

Doktorovová S, Santos DL, Costa I, Andreani T, Souto EB, Silva AM.

Int J Pharm. 2014 Aug 25;471(1-2):18-27. doi: 10.1016/j.ijpharm.2014.05.011. Epub 2014 May 13.

PMID:
24836663
25.

Solid lipid nanoparticles for hydrophilic biotech drugs: optimization and cell viability studies (Caco-2 & HEPG-2 cell lines).

Severino P, Andreani T, Jäger A, Chaud MV, Santana MH, Silva AM, Souto EB.

Eur J Med Chem. 2014 Jun 23;81:28-34. doi: 10.1016/j.ejmech.2014.04.084. Epub 2014 May 2.

PMID:
24819957
26.

The discovery of N-((2H-tetrazol-5-yl)methyl)-4-((R)-1-((5r,8R)-8-(tert-butyl)-3-(3,5-dichlorophenyl)-2-oxo-1,4-diazaspiro[4.5]dec-3-en-1-yl)-4,4-dimethylpentyl)benzamide (SCH 900822): a potent and selective glucagon receptor antagonist.

DeMong D, Dai X, Hwa J, Miller M, Lin SI, Kang L, Stamford A, Greenlee W, Yu W, Wong M, Lavey B, Kozlowski J, Zhou G, Yang DY, Patel B, Soriano A, Zhai Y, Sondey C, Zhang H, Lachowicz J, Grotz D, Cox K, Morrison R, Andreani T, Cao Y, Liang M, Meng T, McNamara P, Wong J, Bradley P, Feng KI, Belani J, Chen P, Dai P, Gauuan J, Lin P, Zhao H.

J Med Chem. 2014 Mar 27;57(6):2601-10. doi: 10.1021/jm401858f. Epub 2014 Feb 26.

PMID:
24527772
27.

In vitro evaluation of permeation, toxicity and effect of praziquantel-loaded solid lipid nanoparticles against Schistosoma mansoni as a strategy to improve efficacy of the schistosomiasis treatment.

de Souza AL, Andreani T, de Oliveira RN, Kiill CP, dos Santos FK, Allegretti SM, Chaud MV, Souto EB, Silva AM, Gremião MP.

Int J Pharm. 2014 Mar 10;463(1):31-7. doi: 10.1016/j.ijpharm.2013.12.022. Epub 2013 Dec 24.

PMID:
24370839
28.

Design of cationic lipid nanoparticles for ocular delivery: development, characterization and cytotoxicity.

Fangueiro JF, Andreani T, Egea MA, Garcia ML, Souto SB, Silva AM, Souto EB.

Int J Pharm. 2014 Jan 30;461(1-2):64-73. doi: 10.1016/j.ijpharm.2013.11.025. Epub 2013 Nov 23.

PMID:
24275449
29.

Experimental factorial design applied to mucoadhesive lipid nanoparticles via multiple emulsion process.

Fangueiro JF, Andreani T, Egea MA, Garcia ML, Souto SB, Souto EB.

Colloids Surf B Biointerfaces. 2012 Dec 1;100:84-9. doi: 10.1016/j.colsurfb.2012.04.014. Epub 2012 May 4.

PMID:
22766285
30.

Current State-of-Art and New Trends on Lipid Nanoparticles (SLN and NLC) for Oral Drug Delivery.

Severino P, Andreani T, Macedo AS, Fangueiro JF, Santana MH, Silva AM, Souto EB.

J Drug Deliv. 2012;2012:750891. doi: 10.1155/2012/750891. Epub 2011 Nov 24.

31.

A divergent and selective synthesis of isomeric benzoxazoles from a single N-Cl imine.

Chen CY, Andreani T, Li H.

Org Lett. 2011 Dec 2;13(23):6300-3. doi: 10.1021/ol202844c. Epub 2011 Nov 8.

PMID:
22067007
32.

HBV-carriers: When is monitoring and surveillance sufficient? (point of view).

Andreani T.

Clin Res Hepatol Gastroenterol. 2011 Dec;35(12):813-8. doi: 10.1016/j.clinre.2011.06.013. Epub 2011 Aug 6. Review.

PMID:
21821479
33.

Need to strictly define hepatitis B virus immunotolerant patients to avoid unnecessary liver biopsy.

Andreani T, Serfaty L, Poupon R, Chazouilleres O.

Gastroenterology. 2008 Dec;135(6):2155-6. doi: 10.1053/j.gastro.2008.08.060. Epub 2008 Nov 8. No abstract available.

PMID:
19000682
34.

Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis.

Corpechot C, Abenavoli L, Rabahi N, Chrétien Y, Andréani T, Johanet C, Chazouillères O, Poupon R.

Hepatology. 2008 Sep;48(3):871-7. doi: 10.1002/hep.22428.

PMID:
18752324
35.

TIPS in hereditary hemorrhagic telangiectasia: never say never.

Chanson N, Carbonell N, Andréani T, Bellaiche G, Cluzel P, Serfaty L, Chazouilleres O, Poupon R.

J Hepatol. 2008 Feb;48(2):373-4. Epub 2007 Dec 3. No abstract available.

PMID:
18093683
36.

Chronic hepatitis B virus carriers in the immunotolerant phase of infection: histologic findings and outcome.

Andreani T, Serfaty L, Mohand D, Dernaika S, Wendum D, Chazouillères O, Poupon R.

Clin Gastroenterol Hepatol. 2007 May;5(5):636-41. Epub 2007 Apr 11.

PMID:
17428739
37.

Treatment of small hepatocellular carcinoma with acetic acid percutaneous injection.

Fartoux L, Arrive L, Andreani T, Serfaty L, Chazouillères O, Tubiana JM, Poupon R, Rosmorduc O.

Gastroenterol Clin Biol. 2005 Dec;29(12):1213-9.

38.

Combination therapy of chronic viral hepatitis B with lamivudine and interferon: better than what?

Andreani T, Serfaty L, Chazouillères O, Poupon R.

J Hepatol. 2002 Apr;36(4):572-3; author reply 573. No abstract available.

PMID:
11943435
39.

[Risks and precautions for the use of lamivudine in patients with chronic hepatitis B virus infection].

Andreani T, Chazouillères O, Calmus Y, Poupon R.

Gastroenterol Clin Biol. 2002 Jan;26(1):51-6. Review. French. No abstract available.

40.

Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone: results of a pilot study.

Serfaty L, Thabut D, Zoulim F, Andreani T, Chazouillères O, Carbonell N, Loria A, Poupon R.

Hepatology. 2001 Sep;34(3):573-7.

PMID:
11526544
41.

Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C.

Serfaty L, Andreani T, Giral P, Carbonell N, Chazouillères O, Poupon R.

J Hepatol. 2001 Mar;34(3):428-34.

PMID:
11322205
42.
43.

Interferon alfa therapy in patients with chronic hepatitis C and persistently normal aminotransferase activity.

Serfaty L, Chazouillères O, Pawlotsky JM, Andreani T, Pellet C, Poupon R.

Gastroenterology. 1996 Jan;110(1):291-5.

PMID:
8536870
44.

[Association of Gougerot-Sjögren syndrome and viral hepatitis C. Apropos of 6 cases].

Wattiaux MJ, Jouan-Flahault C, Youinou P, Cabane J, Andreani T, Serfaty L, Imbert JC.

Ann Med Interne (Paris). 1995;146(4):247-50. French.

PMID:
7653945
45.

Factors predictive of the response to interferon in patients with chronic hepatitis C.

Serfaty L, Giral P, Loria A, Andréani T, Legendre C, Poupon R.

J Hepatol. 1994 Jul;21(1):12-7.

PMID:
7963412
46.

Impact of screening donor blood for alanine aminotransferase and antibody to hepatitis B core antigen on the risk of hepatitis C virus transmission.

Jullien AM, Couroucé AM, Massari V, Maniez M, Finetti P, Brevière D, Girard M, Andréani T, Habibi B.

Eur J Clin Microbiol Infect Dis. 1993 Sep;12(9):668-72.

PMID:
8243482
47.

[Viral hepatitis C].

Bauer V, Bellessort MC, Thevenot N, Andreani T.

Soins. 1991 Mar;(546):37-42. French. No abstract available.

PMID:
1903894
48.

Preventive therapy of first gastrointestinal bleeding in patients with cirrhosis: results of a controlled trial comparing propranolol, endoscopic sclerotherapy and placebo.

Andreani T, Poupon RE, Balkau BJ, Trinchet JC, Grange JD, Peigney N, Beaugrand M, Poupon R.

Hepatology. 1990 Dec;12(6):1413-9.

PMID:
2258157
49.

[Rectal adenocarcinoma in association with lymphoma ("collision tumor")].

Chazouillères O, Andréani T, Boucher JP, Calmus Y, de Sigalony H, Nordlinger R, Poupon R.

Gastroenterol Clin Biol. 1990;14(2):185-6. French. No abstract available.

PMID:
2328885
50.

Successful ablation of a large fibrovascular polyp of the esophagus by endoscopic Nd:YAG laser therapy.

Naveau S, Bedossa P, Mallet L, Turner L, Poynard T, Andréani T, Chaput JC.

Gastrointest Endosc. 1989 May-Jun;35(3):254-6. No abstract available.

PMID:
2759402

Supplemental Content

Loading ...
Support Center